AU6492600A - Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs - Google Patents

Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs

Info

Publication number
AU6492600A
AU6492600A AU64926/00A AU6492600A AU6492600A AU 6492600 A AU6492600 A AU 6492600A AU 64926/00 A AU64926/00 A AU 64926/00A AU 6492600 A AU6492600 A AU 6492600A AU 6492600 A AU6492600 A AU 6492600A
Authority
AU
Australia
Prior art keywords
prodrugs
camptothecin
derivatives
methods
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64926/00A
Other languages
English (en)
Inventor
Zhisong Cao
Beppino C. Giovanella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Christus Stehlin Foundation for Cancer Research
Original Assignee
Christus Stehlin Foundation for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/365,632 external-priority patent/US6096336A/en
Application filed by Christus Stehlin Foundation for Cancer Research filed Critical Christus Stehlin Foundation for Cancer Research
Publication of AU6492600A publication Critical patent/AU6492600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU64926/00A 1999-08-03 2000-07-25 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs Abandoned AU6492600A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09365632 1999-08-03
US09/365,632 US6096336A (en) 1996-01-30 1999-08-03 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US09499684 2000-02-08
US09/499,684 US6352996B1 (en) 1999-08-03 2000-02-08 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
PCT/US2000/020136 WO2001008663A2 (en) 1999-08-03 2000-07-25 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs

Publications (1)

Publication Number Publication Date
AU6492600A true AU6492600A (en) 2001-02-19

Family

ID=43706143

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64926/00A Abandoned AU6492600A (en) 1999-08-03 2000-07-25 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs

Country Status (6)

Country Link
US (1) US6352996B1 (enExample)
EP (1) EP1200068A2 (enExample)
JP (1) JP2003528808A (enExample)
AU (1) AU6492600A (enExample)
CA (1) CA2379660A1 (enExample)
WO (1) WO2001008663A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
EP1299085B1 (en) * 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
PT1432402E (pt) * 2001-10-03 2007-02-28 Celator Pharmaceuticals Inc Composições para administração de combinações de fármacos
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
WO2004054499A2 (en) * 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
AU2003302986A1 (en) * 2002-12-13 2004-07-09 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7550256B2 (en) * 2002-12-13 2009-06-23 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
AU2003300676A1 (en) * 2003-01-03 2004-07-29 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004080819A2 (en) * 2003-03-14 2004-09-23 Aurelium Biopharma Inc. Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
AU2005223654A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
AU2005245018A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
NZ551748A (en) 2004-06-01 2010-02-26 Yakult Honsha Kk Irinotecan formulation
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
KR20070089693A (ko) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
US20060135546A1 (en) * 2004-12-16 2006-06-22 Jagadevappa Basavaraja Methods for the purification of 20(S)- camptothecin
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
ES2275443B1 (es) * 2005-11-30 2008-06-01 Italfarmaco, S.A. Procedimiento de preparacion de liposomas.
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
WO2007106549A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for treating brain cancer
BRPI0714277A2 (pt) * 2006-08-11 2013-04-24 Christus Stehlin Foundation For Cancer Res mÉtodo paa fazer um Éster alifÁtico de camptotecina e Éster alifÁtico de camptotecina
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US7572803B2 (en) * 2007-10-25 2009-08-11 The Christus Stehlin Foundation For Cancer Research Hydrated crystalline esters of camptothecin
US8067432B2 (en) * 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
CN102161680A (zh) * 2011-02-24 2011-08-24 湖南方盛华美医药科技有限公司 磷酰胺酯喜树碱衍生物以及其制备方法、药物组合物和用途
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
BR112014029188B1 (pt) * 2012-05-31 2020-02-11 Terumo Kabushiki Kaisha Veículo sensível ao ph e método de preparação do mesmo, e droga sensível ao ph e composição medicamentosa sensível ao ph contendo o veículo, e método de cultura usando o mesmo
EP2892524B1 (en) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
EP2733821A1 (en) 2012-11-14 2014-05-21 GE Energy Power Conversion Technology Ltd A rotating electrical machine having a segmented stator
WO2014081887A1 (en) 2012-11-20 2014-05-30 Spectrum Pharmaceuticals Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
WO2017156191A1 (en) * 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
WO2021172359A1 (ja) * 2020-02-25 2021-09-02 大日本住友製薬株式会社 Ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
WO2023027032A1 (ja) * 2021-08-23 2023-03-02 住友ファーマ株式会社 自己分解型ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
US4399282A (en) 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
JPS56108787A (en) 1980-01-31 1981-08-28 Sato Yakugaku Kenkyusho:Kk Camptothecin coline salt and its preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4801459A (en) 1986-08-05 1989-01-31 Liburdy Robert P Technique for drug and chemical delivery
US5227380A (en) 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5106742A (en) 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5053512A (en) 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US4894456A (en) 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5180722A (en) 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS6461482A (en) 1987-08-31 1989-03-08 Yakult Honsha Kk Dehydrocamptothecin and production thereof
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5225404A (en) 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
DK0547165T3 (da) 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
WO1992014471A1 (en) 1991-02-21 1992-09-03 Smithkline Beecham Corporation Treatment of non-small cell lung carcinoma
CA2097163C (en) 1992-06-01 2002-07-30 Marianna Foldvari Topical patch for liposomal drug delivery system
US5391745A (en) 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0602361B1 (de) 1992-11-17 1997-01-22 C. Rob. Hammerstein GmbH Rückenlehnengelenk für einen Fahrzeugsitz
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5352789A (en) 1993-02-25 1994-10-04 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5527913A (en) 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
DK0678017T3 (da) 1993-11-05 1998-10-19 Amgen Inc Liposomfremstilling og materialeindkapslingsfremgangsmåde
GB9402934D0 (en) 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
GB9410388D0 (en) 1994-05-24 1994-07-13 Erba Carlo Spa Method for the preparation of 9-amino camptothecin
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5505958A (en) 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture
KR960029336A (ko) * 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5660855A (en) 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US5736156A (en) 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5834012A (en) 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6214836B1 (en) * 1995-06-06 2001-04-10 Dr. Reddy's Research Foundation Water soluble analogues of 20(S)-camptothecin
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
CA2225734C (en) * 1995-06-29 2006-11-14 Lynn Wiese Localized illumination using tir technology
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US5731316A (en) * 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6096336A (en) 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
DE69728152T2 (de) 1996-08-19 2004-08-05 Bionumerik Pharmaceuticals, Inc., San Antonio Hoch-lipophile campothecin-derivate
AU4424797A (en) 1996-09-18 1998-04-14 Dragoco Inc. Liposome encapsulated active agent dry powder composition
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US5922877A (en) 1997-08-05 1999-07-13 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet

Also Published As

Publication number Publication date
EP1200068A2 (en) 2002-05-02
WO2001008663A3 (en) 2001-07-26
US6352996B1 (en) 2002-03-05
JP2003528808A (ja) 2003-09-30
CA2379660A1 (en) 2001-02-08
WO2001008663A2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
AU4564200A (en) Method for treating cancer using camptothecin derivatives and 5-fluorouracil
AU4838600A (en) Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU2212299A (en) Compositions and methods for the treatment of tumor
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
HUP0202492A3 (en) Arylmethyl-carbonylamino-thiazole derivatives process for their preparation and their use as antitumor agents
AU715620C (en) Therapeutic methods and uses
EP1176964B8 (en) Uses of et743 for treating cancer
AU4063600A (en) A method of treating cancer
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU7377200A (en) Combination therapy including camptothecin
AU5042000A (en) Methods of treating proliferative disorders
AU3913900A (en) Radioenhanced cancer treatment using orally administered camptothecin derivatives
AU2001253836A1 (en) Method of treating cancer
AU2001241779A1 (en) Method of treatment of prostate cancer
AU1678900A (en) A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU2001252235A1 (en) A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
AU5097099A (en) Methods and compositions for cancer treatment
AU2292801A (en) Compositions and methods for treatment of breast cancer
AU7373600A (en) Method of potentiating chemotherapy and treating solid tumors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase